Korean Market
EXCH
Daewoong
★

Daewoong Publishes 2025 Corporate Governance Report - Stable Dividend Maintained, Minor Deficiencies Acknowledged, Neutral Impact on Shareholder Value

 
EXCH
Daewoong
★★

Daewoong Files for Domestic Approval of Diabetes Combo Drug Envlozem... Positive Phase 3 Results Expected to Enhance Shareholder Value

 
EXCH
Daewoong
★★

Daewoong's Subsidiary Daewoong Pharmaceutical Gets Mexico Approval for Diabetes Drug Envlo 0.3mg… Expected to Boost Overseas Sales via Latin American Market Entry

 
EXCH
Daewoong
★★★★

Daewoong Pharmaceutical Signs Exclusive Global Technology Introduction Contract for 4-Week Long-Acting Semaglutide Injection for Obesity

 
EXCH
Daewoong
★★★★

Completion of Succession of Licensor Position for mRNA ERA Technology... Securing Right to Receive Up to $239M

 
PERI
Daewoong
★

Daewoong 1Q26 Consolidated Sales KRW 492.7B, OP KRW 47.8B – Routine Quarterly Results

 
EXCH
Daewoong
★★

Daewoong Pharmaceutical Signs Technology Introduction Agreement for 15-PGDH Inhibitor INV-008 (Up to KRW 662.5 Billion)

 
EXCH
Daewoong
★★

Daewoong Pharmaceutical Acquires Licensor Status for mRNA-based ERA Platform

 
EXCH
Daewoong
★★★

Daewoong Pharma Gets Nod for Fexuclue H. pylori Eradication Indication